このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

2017年8月10日 更新者：Biogen

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension

This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).

Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS).

The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores.

Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS.

The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or participant-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.

調査の概要

状態

終了しました

条件

介入・治療

研究の種類

介入

入学 (実際)

889

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アイルランド
      • Dublin、アイルランド、D4
        • Research Site
      • Dublin、アイルランド、D9
        • Research Site
  • アメリカ
    • Arizona
      • Phoenix、Arizona、アメリカ、85013
        • Research Site
      • Tucson、Arizona、アメリカ、85741
        • Research Site
    • California
      • Fullerton、California、アメリカ、92835
        • Research Site
      • Los Angeles、California、アメリカ、90027
        • Research Site
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • Research Site
    • Florida
      • Tampa、Florida、アメリカ、33612
        • Research Site
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • Research Site
      • Lake Barrington、Illinois、アメリカ、60010
        • Research Site
      • Peoria、Illinois、アメリカ、61606
        • Research Site
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Research Site
      • Indianapolis、Indiana、アメリカ、46256
        • Research Site
    • Kansas
      • Kansas City、Kansas、アメリカ、66160
        • Research Site
    • Kentucky
      • Lexington、Kentucky、アメリカ、40536
        • Research Site
      • Lexington、Kentucky、アメリカ、40513
        • Research Site
    • Maryland
      • Baltimore、Maryland、アメリカ、21287
        • Research Site
    • Massachusetts
      • Burlington、Massachusetts、アメリカ、01805
        • Research Site
    • Nebraska
      • Omaha、Nebraska、アメリカ、68198
        • Research Site
    • New Hampshire
      • Lebanon、New Hampshire、アメリカ、03756
        • Research Site
    • New Jersey
      • Teaneck、New Jersey、アメリカ、07666
        • Research Site
    • New York
      • Latham、New York、アメリカ、12110
        • Research Site
      • New York、New York、アメリカ、10029
        • Research Site
    • North Carolina
      • Advance、North Carolina、アメリカ、27006
        • Research Site
      • Charlotte、North Carolina、アメリカ、28207
        • Research Site
      • Raleigh、North Carolina、アメリカ、27607
        • Research Site
    • Ohio
      • Akron、Ohio、アメリカ、44320
        • Research Site
      • Uniontown、Ohio、アメリカ、44685
        • Research Site
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • Research Site
    • Oregon
      • Clackamas、Oregon、アメリカ、97015
        • Research Site
      • Portland、Oregon、アメリカ、97239
        • Research Site
      • Portland、Oregon、アメリカ、97225
        • Research Site
    • Tennessee
      • Nashville、Tennessee、アメリカ、37215
        • Research Site
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • Research Site
    • Washington
      • Seattle、Washington、アメリカ、98101
        • Research Site
    • Wisconsin
      • Green Bay、Wisconsin、アメリカ、54311
        • Research Site
      • Milwaukee、Wisconsin、アメリカ、53215
        • Research Site
  • イギリス
      • Brighton、イギリス、BN2 5BE
        • Research Site
      • London、イギリス、WC1N 3BG
        • Research Site
      • Sheffield、イギリス、S10 2JF
        • Research Site
    • Ayrshire
      • Irvine、Ayrshire、イギリス、KA12 8SS
        • Research Site
    • Birmingham
      • Edgbaston、Birmingham、イギリス、B15 2TH
        • Research Site
    • Devon
      • Exeter、Devon、イギリス、EX2 5DW
        • Research Site
      • Plymouth、Devon、イギリス、PL6 8BX
        • Research Site
    • Greater London
      • London、Greater London、イギリス、SE5 9RS
        • Research Site
      • London、Greater London、イギリス、E1 2AT
        • Research Site
    • London
      • Hammersmith、London、イギリス、W6 8RF
        • Research Site
    • Lothian Region
      • Edinburgh、Lothian Region、イギリス、EH4 2XU
        • Research Site
    • Manchester
      • Salford、Manchester、イギリス、M6 8HD
        • Research Site
    • Merseyside
      • Liverpool、Merseyside、イギリス、L9 7LJ
        • Research Site
    • Norfolk
      • Norwich、Norfolk、イギリス、NR4 7UY
        • Research Site
    • Nottinghamshire
      • Nottingham、Nottinghamshire、イギリス、NG7 2UH
        • Research Site
    • Swansea
      • Morriston、Swansea、イギリス、SA6 6NL
        • Research Site
    • Tyne
      • Newcastle、Tyne、イギリス、NE1 4LP
        • Research Site
  • イスラエル
      • Jerusalem、イスラエル、91120
        • Research Site
      • Ramat Gan、イスラエル、52621
        • Research Site
  • イタリア
      • Bari、イタリア、70124
        • Research Site
      • Florence、イタリア、50134
        • Research Site
      • Genova、イタリア、16132
        • Research Site
      • Milano、イタリア、20122
        • Research Site
      • Milano、イタリア、20132
        • Research Site
      • Naples、イタリア、80138
        • Research Site
      • Napoli、イタリア、80131
        • Research Site
      • Palermo、イタリア、90146
        • Research Site
      • Pavia、イタリア、27100
        • Research Site
      • Rome、イタリア、00189
        • Research Site
      • Rome、イタリア、00176
        • Research Site
    • Modena
      • Baggiovara、Modena、イタリア、41100
        • Research Site
    • Palermo
      • Cefalu、Palermo、イタリア、90015
        • Research Site
    • Varese
      • Gallarate、Varese、イタリア、21013
        • Research Site
  • オランダ
      • Amsterdam、オランダ、1081 HV
        • Research Site
      • Breda、オランダ、4800 RK
        • Research Site
      • Hertogenbosch、オランダ、5223 GZ
        • Research Site
      • Hoorn、オランダ、1624 NP
        • Research Site
      • Nieuwegein、オランダ、3430 EM
        • Research Site
      • Sittard-Geleen、オランダ、6130 MB
        • Research Site
  • カナダ
    • Alberta
      • Calgary、Alberta、カナダ、T2N 2T9
        • Research Site
      • Edmonton、Alberta、カナダ、T6G 2G3
        • Research Site
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6T 1Z3
        • Research Site
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3H 4K4
        • Research Site
    • Ontario
      • Kingston、Ontario、カナダ、K7L 2V7
        • Research Site
      • London、Ontario、カナダ、N6A 5A5
        • Research Site
      • Ottawa、Ontario、カナダ、K1H 8L6
        • Research Site
      • Toronto、Ontario、カナダ、M4N 3M5
        • Research Site
    • Quebec
      • Gatineau、Quebec、カナダ、J9J 0A5
        • Research Site
      • Greenfield Park、Quebec、カナダ、J4V 2J2
        • Research Site
      • Montreal、Quebec、カナダ、H2L 4M1
        • Research Site
      • Montreal、Quebec、カナダ、H3A 2B4
        • Research Site
  • スウェーデン
      • Göteborg、スウェーデン、41345
        • Research Site
      • Stockholm、スウェーデン、17176
        • Research Site
      • Stockholm、スウェーデン、14186
        • Research Site
      • Stockholm、スウェーデン、18288
        • Research Site
      • Umeå、スウェーデン、90185
        • Research Site
      • Örebro、スウェーデン、70185
        • Research Site
  • スペイン
      • Barcelona、スペイン、08035
        • Research Site
      • Barcelona、スペイン、08036
        • Research Site
      • Barcelona、スペイン、08041
        • Research Site
      • El Palmar、スペイン、30120
        • Research Site
      • Madrid、スペイン、28034
        • Research Site
      • Madrid、スペイン、28040
        • Research Site
      • Majadahonda、スペイン、28222
        • Research Site
      • Málaga、スペイン、29010
        • Research Site
      • Santa Cruz de Tenerife、スペイン、38010
        • Research Site
      • Sevilla、スペイン、41009
        • Research Site
  • チェコ
      • Brno、チェコ、65691
        • Research Site
      • Olomouc、チェコ、77520
        • Research Site
      • Praha、チェコ、12111
        • Research Site
    • Bohemia
      • Hradec Kralove、Bohemia、チェコ、50005
        • Research Site
  • デンマーク
      • Arthus C、デンマーク、8000
        • Research Site
      • Esbjerg、デンマーク、6700
        • Research Site
      • Glostrup、デンマーク、2600
        • Research Site
      • København Ø、デンマーク、2100
        • Research Site
      • Odense、デンマーク、5000
        • Research Site
  • ドイツ
    • Baden Wuerttemberg
      • Bad Wilbad、Baden Wuerttemberg、ドイツ、75323
        • Research Site
      • Tuebingen、Baden Wuerttemberg、ドイツ、72076
        • Research Site
    • Baden-Wuerttemberg
      • Bad Mergentheim、Baden-Wuerttemberg、ドイツ、97980
        • Research Site
    • Bayern
      • Muenchen、Bayern、ドイツ、81675
        • Research Site
      • Muenchen、Bayern、ドイツ、81377
        • Research Site
    • Brandenburg
      • Hennigsdorf、Brandenburg、ドイツ、16761
        • Research Site
      • Teupitz、Brandenburg、ドイツ、15755
        • Research Site
    • Hessen
      • Kassel、Hessen、ドイツ、34121
        • Research Site
    • Nordrhein Westfalen
      • Duesseldorf、Nordrhein Westfalen、ドイツ、40225
        • Research Site
      • Muenster、Nordrhein Westfalen、ドイツ、48149
        • Research Site
    • Sachsen
      • Dresden、Sachsen、ドイツ、01307
        • Research Site
  • フィンランド
      • Jyväskylä、フィンランド、40620
        • Research Site
      • Tampere、フィンランド、33520
        • Research Site
      • Turku、フィンランド、20520
        • Research Site
  • フランス
      • Bordeaux、フランス、33076
        • Research Site
    • Alpes Maritimes
      • Nice、Alpes Maritimes、フランス、06002
        • Research Site
    • Bouches-du-Rhône
      • Marseille cedex 5、Bouches-du-Rhône、フランス、13385
        • Research Site
    • Loire Atlantique
      • Nantes、Loire Atlantique、フランス、44093
        • Research Site
    • Meurthe et Moselle
      • Nancy、Meurthe et Moselle、フランス、54035
        • Research Site
    • Nord
      • Lille Cedex、Nord、フランス、59000
        • Research Site
    • Rhone
      • Bron cedex、Rhone、フランス、69677
        • Research Site
    • Somme
      • Salouel、Somme、フランス、80054
        • Research Site
  • ベルギー
      • La Louviere、ベルギー、7100
        • Research Site
      • Melsbroek、ベルギー、1820
        • Research Site
      • Overpelt、ベルギー、3900
        • Research Site
  • ポーランド
      • Bialystok、ポーランド、15-276
        • Research Site
      • Gdansk、ポーランド、80-803
        • Research Site
      • Katowice、ポーランド、40-749
        • Research Site
      • Katowice、ポーランド、40-595
        • Research Site
      • Katowice、ポーランド、40-635
        • Research Site
      • Krakow、ポーランド、31-505
        • Research Site
      • Lodz、ポーランド、90-324
        • Research Site
      • Lublin、ポーランド、20-954
        • Research Site
      • Olsztyn、ポーランド、10-561
        • Research Site
      • Plewiska、ポーランド、62-064
        • Research Site
      • Poznan、ポーランド、61-853
        • Research Site
      • Szczecin、ポーランド、70-111
        • Research Site
      • Warszawa、ポーランド、04-141
        • Research Site
      • Warszawa、ポーランド、02-097
        • Research Site
      • Warszawa、ポーランド、01-697
        • Research Site
      • Warszawa-Miedzylesie、ポーランド、04-749
        • Research Site
      • Wroclaw、ポーランド、50-556
        • Research Site
  • ロシア連邦
      • Belgorod、ロシア連邦、308007
        • Research Site
      • Kazan、ロシア連邦、420021
        • Research Site
      • Kazan、ロシア連邦、420097
        • Research Site
      • Moscow、ロシア連邦、127015
        • Research Site
      • St. Petersburg、ロシア連邦、197110
        • Research Site
      • Tyumen、ロシア連邦、625000
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年～58年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Key Inclusion Criteria (Part 1):

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.
  • SPMS defined as relapsing-remitting disease followed by progression of disability independent of or not explained by multiple sclerosis (MS) relapses for at least 2 years.
  • EDSS score of 3.0 to 6.5, inclusive.
  • Multiple Sclerosis Severity Score of 4 or higher.
  • Documented confirmed evidence of disease progression independent of clinical relapses over the 1 year prior to enrollment as defined in the Study Reference Guide.

Key Exclusion Criteria (Part 1):

  • Relapsing remitting multiple sclerosis (RRMS) or primary progressive MS as defined by the revised McDonald Committee criteria.
  • Clinical relapse (within 3 months) prior to randomization.
  • T25FW test of >30 seconds during the screening period.
  • Any value below the lower limit of normal for blood levels of leukocytes, lymphocytes, or neutrophils.
  • Considered by the Investigator to be immunocompromised based on medical history, physical examination, laboratory testing, or any other testing required by local guidelines, or due to prior immunosuppressive or immunomodulating treatment.
  • Subjects for whom MRI is contraindicated (i.e., have pacemakers or other contraindicated implanted metal devices, are allergic to gadolinium, or have claustrophobia that cannot be medically managed).
  • History of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease that would preclude participation in a clinical study.
  • History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
  • Known history of or positive test result for human immunodeficiency virus.
  • Positive test result for hepatitis C virus (test for hepatitis C virus antibody or hepatitis B virus (test for hepatitis B surface antigen and/or hepatitis B core antibody).
  • History of transplantation or any anti-rejection therapy.
  • Presence of any infectious disease (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to screening.
  • History of progressive multifocal leukoencephalopathy or other opportunistic infections.

Treatment History (Part 1)

  • Any prior treatment with cell-depleting therapies, including total lymphoid irradiation, cladribine, rituximab, alemtuzumab, or bone marrow ablation.
  • Any prior treatment with natalizumab.
  • Treatment with mitoxantrone, cyclophosphamide, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, T cell or T cell receptor vaccination, fingolimod, daclizumab, or cytapheresis within 6 months prior to randomization.
  • Treatment with intravenous or oral corticosteroids, intravenous immunoglobulin, or plasmapheresis for treatment of MS within the 3 months prior to randomization.
  • Treatment with glatiramer acetate or any interferon beta preparations within 4 weeks prior to randomization.
  • Treatment with 4-aminopyridine within 30 days prior to randomization, unless a stable dose has been maintained for at least 30 days prior to randomization and will be continued for the course of this study.

Key Inclusion Criteria (Part 2):

  • Subjects must have participated in and completed Part 1 per protocol, and have documented assessment attempts for EDSS, T25FW, and 9HPT prior to first open-label dosing.

Key Exclusion Criteria (Part 2):

  • Subjects with any significant change in clinical status, including laboratory tests that, in the opinion of the Investigator, would make them unsuitable to participate in this extension study. The Investigator must re-review the subject's medical fitness for participation and consider any diseases that would preclude treatment.
  • Subjects who discontinued study treatment in Part 1 OR had fewer than 20 infusions in Part 1 OR missed 2 or more consecutive infusions in Part 1.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的：natalizumab
In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
薬：ナタリズマブ
治療群で指定されたとおりに投与
他の名前：
  • ティサブリ
  • BG00002
実験的：Placebo
In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
薬：ナタリズマブ
治療群で指定されたとおりに投与
他の名前：
  • ティサブリ
  • BG00002
薬：Placebo
Matched placebo in part 1

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)
時間枠：Up to 96 weeks (2 years)

Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):

  • Confirmed progression in EDSS (EDSS score increased from baseline [BL] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);
  • Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);
  • Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).

The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.
Up to 96 weeks (2 years)
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠：218 weeks
AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.
218 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Part 1: Percentage of Participants With a T25FW Response
時間枠：Up to 96 weeks
T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.
Up to 96 weeks
Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)
時間枠：Baseline and Week 96
MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.
Baseline and Week 96
Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire
時間枠：Baseline and Week 96
The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND.
Baseline and Week 96
Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score
時間枠：Baseline and Week 96
The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline and Week 96
Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96
時間枠：Week 24 and Week 96
Whole brain volume as measured by MRI.
Week 24 and Week 96
Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores
時間枠：Up to 96 weeks

The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:

  • an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or
  • an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.

A confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.
Up to 96 weeks
Part 2: Percentage of Participants With Disability Worsening at 156 Weeks
時間枠：Week 156
Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS > 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.
Week 156
Part 2: Absolute Change From Baseline (Part 1) in T25FW
時間枠：Baseline (Part 1) and Weeks 156, 204
The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in T25FW
時間枠：Baseline (Part 1) and Weeks 156, 204
The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)
時間枠：Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)
時間枠：Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)
時間枠：Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)
時間枠：Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in EDSS
時間枠：Baseline (Part 1) and Weeks 156, 204
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in EDSS
時間枠：Baseline (Part 1) and Weeks 156, 204
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)
時間枠：Baseline (Part 1) and Weeks 156 and 204
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in the 6MWT
時間枠：Baseline (Part 1) and Weeks 156, 204
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score
時間枠：Baseline (Part 1) and Weeks 156 and 204
The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score
時間枠：Baseline (Part 1) and Weeks 156, 204
The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)
時間枠：Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
Part 2: Percentage Change From Baseline (Part 1) in the SDMT
時間枠：Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire
時間枠：Part 2 Baseline (Week 108) and Weeks 156 and 204
The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Part 2 Baseline (Week 108) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire
時間枠：Part 2 Baseline (Week 108) and Weeks 156 and 204
The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Part 2 Baseline (Week 108) and Weeks 156 and 204
Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume
時間枠：Week 24 (Part 1) and Weeks 156 and 204
Whole brain volume as measured by MRI.
Week 24 (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume
時間枠：Baseline (Part 1) and Weeks 156 and 204
Whole grey matter brain volume as measured by MRI.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Summary of New/Enlarging T2 Lesion Counts
時間枠：Baseline (Part 1) up to Week 204
New or enlarging T2 lesions as measured by MRI.
Baseline (Part 1) up to Week 204
Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions
時間枠：Baseline (Part 1) and Weeks 156 and 204
New or enlarging T2 lesions as measured by MRI.
Baseline (Part 1) and Weeks 156 and 204

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Biogen

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2011年9月13日

一次修了 (実際)

2015年7月28日

研究の完了 (実際)

2016年4月13日

試験登録日

最初に提出

2011年7月21日

QC基準を満たした最初の提出物

2011年8月11日

最初の投稿 (見積もり)

2011年8月12日

学習記録の更新

投稿された最後の更新 (実際)

2017年9月11日

QC基準を満たした最後の更新が送信されました

2017年8月10日

最終確認日

2017年8月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 101MS326
  • 2010-021978-11 (EudraCT番号)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

類似の治験を検索

スポンサーと協力者

医学的状態

薬物療法

CROs by country

CROs in Congo

条件

まれな病気

薬物療法

ダイエットサプリメント

スポンサー/協力者

場所

3
購読する